Why is "CureVac" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-07-21 05:17:14
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
CureVac entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-07-21 and was most recently seen on 2026-07-21.
Wikipedia Overview
CureVac is a biopharmaceutical company based in Tübingen, Germany that develops therapies based on messenger RNA (mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
-
CureVac Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
-
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
-
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Yahoo Finance
-
CureVac takes Moderna to court over mRNA vaccine patents - European Biotechnology Magazine
-
BioNTech to slash 1,860 jobs, exit sites in Germany and Singapore in major manufacturing pullback - Fierce Pharma
-
Germany: BioNTech shutting down COVID vaccine production - DW.com
-
CureVac Is Focusing On MRNA Cancer Vaccines, CFO Says Lakers (jBcO3wg9KS) - Mshale
-
Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ - Endpoints News
-
White & Case advises Berenberg on BioNTech’s public exchange offer for CureVac shares - White & Case LLP
-
CureVac shares to be delisted from Nasdaq following BioNTech acquisition - Investing.com
-
New energy Special Report; CureVac sues Moderna; landmark Hikma hearing; EU on USTR watchlist; Samsung v ZTE ruling; plus much more - IAM Patent
-
BioNTech Completes Acquisition of CureVac with 86.75% Share Tendered - Quiver Quantitative
-
CureVac Sues Moderna for Patent Infringement Over COVID-19 Vaccine - Global Banking & Finance Review
-
CureVac targets Moderna with 10-patent suit over Spikevax - Life Sciences IP Review
-
CureVac (CVAC) Earnings Date and Reports 2026 - MarketBeat
-
BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V. - Yahoo Finance
-
CureVac sues Moderna over mRNA vaccine patents - Investing.com
-
Moderna counters CureVac patent lawsuit over Covid-19 vaccines - Investing.com
-
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
-
What went wrong with CureVac's highly anticipated new mRNA vaccine for COVID-19? - Science | AAAS
-
BioNTech completes CureVac acquisition - Health Tech World
-
Bayer, CureVac form alliance on COVID vaccine - The Guardian Nigeria News
-
CureVac Announces Voting Results of Extraordinary General Meeting - Investing News Network
-
GSK and CureVac to restructure collaboration into new licensing agreement - GSK
-
CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha
-
CureVac files Covid-19 vaccine lawsuit against Moderna - CDR News
-
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal - BioPharma Dive
-
GSK and CureVac announce strategic mRNA technology collaboration - GSK
-
MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines - UT MD Anderson
-
Moderna sued by CureVac, continuing covid jab maker’s highly eventful start to 2026 - IAM Patent
-
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - Reuters
-
EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV) - European Medicines Agency (EMA)
-
German court suspends mRNA patent trial against BioNTech - Reuters
-
GSK and CureVac to develop next generation mRNA COVID-19 vaccines - GSK
-
CureVac, GSK's experimental COVID variant vaccine effective in mice -study - Reuters
-
BioNTech buys German mRNA vaccine peer CureVac in $1.2B all-stock deal - Fierce Biotech
-
Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes over - Endpoints News
-
CureVac COVID vaccine let-down spotlights mRNA design challenges - Nature
-
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer - GlobeNewswire
-
Moderna says CureVac broke agreement by suing over COVID vaccine patents - TradingView
-
CureVac scales back mRNA manufacturing for coronavirus vaccine - BioPharma Dive
-
BioNTech to Acquire CureVac in $1.25B Deal to Advance mRNA Cancer Therapies - BioPharm International
-
BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition - Pharmaceutical Technology
-
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition - BioSpace
-
Novartis set to deliver 50 mln CureVac COVID-19 vaccines this year - Reuters
-
CureVac Collaboration - Gates Foundation
-
GSK buys COVID, influenza vaccines from retrenching CureVac - Reuters
-
CureVac’s Covid-19 Vaccine Disappoints in Clinical Trial (Published 2021) - The New York Times
-
GSK pays CureVac $430M for mRNA vaccines against flu and COVID—as partner lays off 30% - Fierce Biotech
-
CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech - Reuters
-
CureVac touts 'progress' as German court suspends infringement proceedings against BioNTech - Fierce Pharma
-
CureVac says COVID vaccine produced immune response in early-stage trial - Reuters
-
Battle for the Billionth Vaccine: Moderna and CureVac Clash in Patent War Over COVID Shot - Судово-юридична газета
-
BioNTech plans acquisition of CureVac while global mRNA dispute pending - JUVE Patent
-
CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 - CEPI
-
CEPI awards US $34million contract to CureVac to advance The RNA Printer™–a mRNA vaccine platform that can rapidly combat multiple diseases - CEPI
-
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging - BioSpace
-
GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech - Pharmaceutical Executive
-
GSK set for over $500M from mRNA patent settlement between BioNTech, CureVac, Pfizer - FirstWord Pharma
-
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine - Nature
-
GSK and CureVac Enter into Licensing Agreement - BioPharm International
-
CureVac CEO replaced in midst of biotech’s coronavirus push - BioPharma Dive
-
GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership - STAT
-
CureVac aims to raise up to $245 million in U.S. IPO - CNBC
-
CureVac to cut costs in restructuring - BioPharma Dive
-
Coronavirus: CureVac vaccine only 47% effective - DW.com
-
CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy - Reuters
-
CureVac cuts jobs, licenses out vaccines to GSK - BioPharma Dive
-
Setback for CureVac in the UK - JUVE Patent
-
GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine - Clinical Trials Arena
-
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News
-
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
-
CureVac announces positive Phase II Covid-19 vaccine trial data - Clinical Trials Arena
-
Acuitas sues CureVac for credit on COVID-19 vaccine patents - Reuters
-
CureVac's COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant - Fierce Biotech
-
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims - Reuters
-
BioNTech to buy fellow German mRNA firm CureVac - Chemical & Engineering News
-
Q&A with CureVac: resolving the ultra-cold chain logistics of Covid-19 mRNA vaccines - Pharmaceutical Technology
-
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion - WSJ
-
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
-
BioNTech to buy rival mRNA firm CureVac for $1.25bn - pharmaphorum
-
All-stock deal: BioNTech bags mRNA vaccine rival CureVac for $1.25bn - BioXconomy
-
CureVac initiates H5N1 avian influenza vaccine study - Clinical Trials Arena
-
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech - pharmaphorum
-
BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes - MedCity News
-
CureVac CEO on the company's IPO and Covid-19 vaccine research - CNBC
-
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights - Reuters
-
U.S. Offered ‘Large Sum’ to German Company for Access to Coronavirus Vaccine Research, German Officials Say - The New York Times
-
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - Yahoo! Finance Canada
-
CureVac scores $85M loan to scale COVID-19 shot manufacturing at German site - Fierce Pharma
-
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents - Reuters
-
mRNA patent wars kick into higher gear during dog days of summer - JUVE Patent
-
This New Covid Vaccine Could Bring Hope to the Unvaccinated World (Published 2021) - The New York Times
-
CureVac ramps up COVID-19 mRNA vaccine effort as Moderna analysts raise questions about animal data - Fierce Biotech
-
GSK joins forces with CureVac to manufacture its Covid-19 vaccine — and to develop another - STAT
-
CureVac Announces Positive Phase II Data For mRNA Flu Vaccine - Inside Precision Medicine
-
As alarm grows over Europe's dwindling vaccine supplies, Bayer could offer its factories to the cause - Fortune
-
CureVac Joins BioNTech: €1.25B Deal Marks New Era in mRNA - Oncodaily
-
German court quashes CureVac patent after challenge by BioNTech - Reuters
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.